NCT06755359招募中不适用
A Safety Study of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 24
- 主要终点
- Safety - Serious adverse events
研究概览
简要总结
A unique approach for cancer treatment including radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor for the treatment of Locally Advanced Pancreatic Cancer .
详细描述
This study will be a prospective, interventional, open label, single arm, multiple center study.
Patients who have been previously treated with 8 - 12 cycles of mFOLFIRINOX will undergo DaRT insertion, with the goal of making their tumor resectable. Three (3) days after DaRT insertion, patients will begin taking Capecitabine for 2 months. Every 2 months after DaRT insertion, the patient will be assessed to determine if their tumor is surgically resectable, if they should continue with therapy, or if they should pause therapy. The trial will end 12 months after DaRT insertion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically and/or cytologically proven locally advanced pancreatic adenocarcinoma
- •Target lesion is technically amenable for Alpha DaRT sources implantation.
- •Measurable lesion per RECIST (version 1.1) criteria
- •Stable disease or tumor response per RECIST (version 1.1) criteria compared to before initiation of mFOLFIRINOX
- •Lesion size ≤ 5 cm in the longest diameter
- •Interstitial radiation indication validated by a multidisciplinary team which includes an oncologist, a radiation oncologist, radiologist, gastroenterologist and a surgeon specialized in pancreatic oncology in the case that a surgical emergency occurs during the procedure
- •Patients have received 8 - 12 cycles of mFOLFIRINOX
- •ECOG Performance Status Scale 0 - 1
- •Life expectancy is more than 6 months
- •WBC ≥ 3500/µl, granulocyte ≥ 1500/µl
- •Platelet count ≥60,000/µl
- •Creatinine ≤1.9 mg/dL
- •AST and ALT ≤ 2.5 X upper limit of normal (ULN)
- •INR < 1.4 for patients not on Warfarin
- •Age ≥18 years old
- •Subjects are willing and able to sign an informed consent form
- •Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after initiation of Alpha DaRT therapy
- •Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after DaRT insertion.
排除标准
- •Concomitant immunotherapy within the past 4 weeks.
- •Patients with metastatic disease
- •Borderline unresectable pancreatic cancer, and/or cases fit for surgical exploration unless patient refuses surgery.
- •Known hypersensitivity to any of the components of the treatment.
- •Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.
- •Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.
- •Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.
- •Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, low risk prostate cancer, or in situ cervical cancer.
- •Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.
- •Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
- •Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.
- •High probability of protocol non-compliance (in opinion of investigator).
- •Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.
研究组 & 干预措施
DaRT Seeds
Experimental
Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
干预措施: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) (Device)
结局指标
主要结局
Safety - Serious adverse events
时间窗: from Day 0 , up to 12 months
Safety will be determined according to the overall incidence of device related SAEs with severity graded according to CTCAE v5.0 criteria
次要结局
- Efficacy - tumor response(Day 0 , up to 12 months)
- Efficacy - overall survival(Day 0 , up to 12 months)
- Efficacy - Progression-free survival(Day 0 , up to 12 months)
- Efficacy - Percentage of R0/R1 resected patients(Day 0 , up to 12 months)
- Efficacy - percentage of patients with tumors that became surgically respectable after DaRT treatment(Day 0 , up to 12 months)
研究者
研究点 (24)
Loading locations...
相似试验
招募中
不适用
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous TumorsCutaneous MetastasisSkin CancerCutaneous TumorNCT04068155Alpha Tau Medical LTD.80
招募中
不适用
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.Mucosal Neoplasm of Oral CavitySoft Tissue NeoplasmSkin CancerNCT03889899Alpha Tau Medical LTD.30
招募中
不适用
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue NeoplasiaMucosal Neoplasm of Oral CavitySoft Tissue NeoplasmSkin CancerNCT04534127Alpha Tau Medical LTD.56
已完成
不适用
Alpha Radiation Emitters Device for the Treatment of Squamous Cell CarcinomaSquamous Cell CarcinomaNCT03015883Alpha Tau Medical LTD.28
进行中（未招募）
不适用
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)Mucosal Neoplasm of Oral CavitySoft Tissue NeoplasmSkin CancerNCT03737734Alpha Tau Medical LTD.30